Parse Biosciences and Nomic Bio Partner to Develop 100 Million-Cell AI-Ready Dataset for Immune Biology

manufacturing-news
Image Courtesy: Pixabay

Parse Biosciences, a QIAGEN company and provider of scalable single-cell sequencing solutions, has partnered with Nomic Bio, a specialist in high-throughput proteomic profiling, to develop Cascade, a foundational dataset comprising 100 million cells to advance understanding of the human immune response.

The multimodal dataset is designed to provide pharmaceutical and biotechnology companies with detailed cellular- and protein-level insights into immune biology, supporting the identification and validation of potential drug targets. Leading industry players, including GSK, Pfizer, Sanofi, Graph Therapeutics and Turbine, have already made foundational partner commitments, reflecting demand for large-scale multimodal data to support drug discovery.

Cascade will combine 100 million single-cell RNA sequencing (RNA-seq) profiles with more than 11,000 proteomic secretome profiles. It will capture the responses of different immune cell types to more than 150,000 individual and combinatorial cytokine and drug perturbation conditions across multiple timepoints. By pairing transcriptomic and proteomic measurements of the same immune responses over time, the resource will help researchers examine the mechanisms underlying immune signalling and address data gaps in the development of predictive virtual cell models.

Single-cell RNA-seq data will be generated at Parse’s GigaLab, a high-throughput service laboratory with the capacity to profile billions of cells annually. The resulting data will be paired with proteomic secretome measurements produced using Nomic’s Omini 1000 platform, which measures more than 1,000 secreted proteins across samples.

“Biological AI modeling has hit a data bottleneck. Despite their central role in drug discovery, there is a surprisingly small amount of available data measuring the human’s immune response to key perturbations like cytokines and other drugs. Cascade is a critical step to revealing these interactions, and we expect to dramatically improve the predictive power of our partner’s AI models as a result,” said Charlie Roco, Co-founder and Chief Technology Officer at Parse Biosciences.

Milad Dagher, Co-founder and CEO of Nomic Bio, said: “AI models of immune biology need to capture not only how cell states change, but also the protein signals cells use to communicate. Cascade brings quantitative, time-resolved protein measurements together with single-cell data at a scale that can help researchers model how immune responses develop and predict how they change under new perturbations.”

Nomic was founded to make measuring biology easier and enable scientists to extend lives by making proteomics accessible, scalable and routine. Powered by its proprietary nELISA® technology, Nomic delivers large-scale, quantitative and cost-effective protein data to accelerate discovery, development and translation. Its end-to-end service combines flexible content, expert support and analysis-ready outputs, enabling proteomics to be integrated across drug and biomarker development. Its mission is to make proteomics ubiquitous for modern biology. For more information, visit nomic.bio or follow the company on LinkedIn.

Parse Biosciences, a QIAGEN company, is a global life sciences company focused on accelerating progress in human health and scientific research. Its scalable single-cell sequencing approach enables researchers to conduct studies across areas including cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development and the immune system.